AR127587A1 - LIPID CONJUGATION TO DIRECT OLIGODENDROCYTES OF THE CENTRAL NERVOUS SYSTEM - Google Patents

LIPID CONJUGATION TO DIRECT OLIGODENDROCYTES OF THE CENTRAL NERVOUS SYSTEM

Info

Publication number
AR127587A1
AR127587A1 ARP220103039A ARP220103039A AR127587A1 AR 127587 A1 AR127587 A1 AR 127587A1 AR P220103039 A ARP220103039 A AR P220103039A AR P220103039 A ARP220103039 A AR P220103039A AR 127587 A1 AR127587 A1 AR 127587A1
Authority
AR
Argentina
Prior art keywords
oligodendrocytes
nervous system
central nervous
direct
lipid conjugation
Prior art date
Application number
ARP220103039A
Other languages
Spanish (es)
Inventor
Bob Dale Brown
Maire Jung
Travis Grim
Matthew Costales
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of AR127587A1 publication Critical patent/AR127587A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

La presente invención proporciona conjugados de oligonucleótidos que inhiben o reducen la expresión de genes diana en los oligodendrocitos del sistema nervioso central. Además se proporcionan composiciones que incluyen los mismos y usos de los mismos, en particular usos relativos al tratamiento de enfermedades, trastornos y/o afecciones asociadas con la expresión de un gen diana de oligodendrocito en el SNC.The present invention provides oligonucleotide conjugates that inhibit or reduce the expression of target genes in oligodendrocytes of the central nervous system. Additionally provided are compositions including the same and uses thereof, in particular uses relating to the treatment of diseases, disorders and/or conditions associated with the expression of an oligodendrocyte target gene in the CNS.

ARP220103039A 2021-11-05 2022-11-04 LIPID CONJUGATION TO DIRECT OLIGODENDROCYTES OF THE CENTRAL NERVOUS SYSTEM AR127587A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163276409P 2021-11-05 2021-11-05

Publications (1)

Publication Number Publication Date
AR127587A1 true AR127587A1 (en) 2024-02-07

Family

ID=86242050

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103039A AR127587A1 (en) 2021-11-05 2022-11-04 LIPID CONJUGATION TO DIRECT OLIGODENDROCYTES OF THE CENTRAL NERVOUS SYSTEM

Country Status (3)

Country Link
AR (1) AR127587A1 (en)
TW (1) TW202340462A (en)
WO (1) WO2023081822A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947683A1 (en) * 2019-04-04 2022-02-09 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
EP4114947A1 (en) * 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases

Also Published As

Publication number Publication date
TW202340462A (en) 2023-10-16
WO2023081822A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
Ip et al. Cycloastragenol is a potent telomerase activator in neuronal cells: implications for depression management
AR112779A1 (en) NUCLEOTIDE COMPOSITIONS AND RELATED METHODS
CL2020002401A1 (en) Arni compositions of 17 b-hydroxysteroid dehydrogenases type 13 (hsd17b13) and methods of use thereof.
MX2020003965A (en) Gene therapies for lysosomal disorders.
CL2020002053A1 (en) Methods and compositions for macrophage polarization.
BR112021019880A2 (en) Gene therapies for lysosomal disorders
CL2022002837A1 (en) Antibody-drug conjugates comprising sting agonists (divisional 202202711)
MX2020004005A (en) Gene therapies for lysosomal disorders.
UY30097A1 (en) THERAPEUTIC USES OF RTP801 INHIBITORS
AR047990A1 (en) THERAPY IN WHICH DERIVATIVES OF 1-CYCLOHEXAN AMINO ARE USED FOR THE TREATMENT OF CONDUCT DISORDERS ASSOCIATED WITH ALZHEIMER'S DISEASE
BR112014019357A8 (en) TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANC AND PARP INHIBITORS
CL2021002877A1 (en) Kcnt1 gene inhibitors, compositions and uses for neurological disorders
CL2021002876A1 (en) Kcnt1 gene inhibitors, compositions and uses for neurological disorders
CO2021007402A2 (en) Supply Constructs for Transcytosis and Related Methods
MX2020004600A (en) Oligonucleotide constructs and uses thereof.
BR112018013084A2 (en) combination treatments comprising administration of imidazopyrazinones
CL2022003369A1 (en) Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
UY30042A1 (en) NEW DERIVATIVES OF ALQUILFOSFOLÍPIDOS WITH REDUCED CYTOTOXICITY AND USES OF THE SAME.
DOP2023000223A (en) COMPOSITIONS AND METHODS FOR INHIBITING KETOHEXOKINASE (KHK)
BR112018013247A2 (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and / or cognitive disorders
CL2021001488A1 (en) Mutated piggybac transposase
BR112022009710A2 (en) COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
CL2022001503A1 (en) Human chromosome 9 open reading frame 72 (c9orf72) arni agents, compositions
BR112023000428A2 (en) METHODS AND COMPOSITIONS TO TREAT EPILEPSY
CL2022002521A1 (en) Compositions and methods to inhibit the expression of angptl3